Details for New Drug Application (NDA): 011751
✉ Email this page to a colleague
NDA 011751 describes PROLIXIN, which is a drug marketed by Apothecon and Bristol Myers Squibb and is included in five NDAs. Additional details are available on the PROLIXIN profile page.
The generic ingredient in PROLIXIN is fluphenazine enanthate. There are nineteen drug master file entries for this compound. Additional details are available on the fluphenazine enanthate profile page.
The generic ingredient in PROLIXIN is fluphenazine enanthate. There are nineteen drug master file entries for this compound. Additional details are available on the fluphenazine enanthate profile page.
Summary for 011751
| Tradename: | PROLIXIN |
| Applicant: | Apothecon |
| Ingredient: | fluphenazine hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
